Atlanta teenager gets new chance at life after medical emergency
An Atlanta teenager and Clark Atlanta University student is getting a chance to get her life back together after a terrifying ordeal that put her in the hospital.
Channel 2's Linda Stouffer spoke to Onyx Middleton and her mother, Cherise, about the condition that looked like a psychiatric issue, but was really a medical emergency.
It all happened last year while her mother says Onyx was in class.
'She just started crying out of the blue, it became hysterical screaming,' Cherise said.
[DOWNLOAD: Free WSB-TV News app for alerts as news breaks]
That's what took Onyx from the classroom to critical care.
Her mom said it looked like Onyx was having a mental breakdown and was transferred to a mental health facility.
'Yeah, they thought it was schizophrenia,' Cherise said.
It wasn't until medical testing in the intensive care unit at Children's Healthcare of Atlanta that the family got an explanation.
TRENDING STORIES:
Today marks 20 years since deadly Fulton County Courthouse shooting rampage
Atlanta police confirm arrest of man accused of slashing homeless tents
Teen flips attacker during brawl over prom dress in Gwinnett, police say
'Honestly a year ago? I don't remember much at all,' Onyx told Channel 2 Action News.
A doctor at Children's Healthcare of Atlanta was able to diagnose her with an auto-immune condition called anti-NMDA receptor encephalitis.
'It basically shuts down a part of my brain and makes me have seizures,' Onyx said.
Pediatric neurologist Dr. Varun Kannan told Stouffer that it's possible they'll never know exactly what triggered Onyx's immune system to attack her body, but the medical team at Children's Healthcare of Atlanta treated her quickly and carefully with immunotherapy medication.
Kannan said it's easy to miss the diagnosis of anti-NMDA receptor encephalitis because it looks so similar to a mental health crisis.
'I think with early diagnosis and aggressive treatment, as Onyx received, there can be a really happy outcome,' Kannan said. 'There are red flag symptoms, so if you have sudden onset psychosis in a previously healthy teenage young adult, or symptoms like seizures, you really should ask a neurologist 'could this be something else?''
Anti-NMDA receptor encephalitis has only been studied in the past 20 years.
For Onyx, after 118 days in the hospital, she's sharing her journey on social media, hoping the next young adult with strange symptoms finds hope.
Onyx told Channel 2 Action News that she's planning her college comeback now.
'I definitely want to go back and get my degree,' she said.
[SIGN UP: WSB-TV Daily Headlines Newsletter]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
14 hours ago
- Business Wire
Arialys Therapeutics Publishes Preclinical Data in Nature Communications Supporting ART5803 as a First-in-Class Precision Therapeutic for Anti-NMDA Receptor Autoimmune Neuropsychiatric Disease
LA JOLLA, Calif.--(BUSINESS WIRE)-- Arialys Therapeutics, a clinical-stage biotechnology company pioneering new precision medicines for autoimmune neuropsychiatric diseases, today announced the publication of preclinical data in Nature Communications demonstrating that its lead drug candidate, ART5803, effectively blocks the underlying disease mechanism in anti-NMDA receptor encephalitis (ANRE) and rapidly reverses behavioral symptoms in a non-human primate model. The findings support the continued clinical development of ART5803 as a first-in-class, targeted therapeutic. The company is currently completing Phase 1 safety studies for ART5803 and plans Phase 2 evaluation in anti-NMDA receptor encephalitis (ANRE) and autoimmune psychosis patients in the second half of 2025. 'This study underscores the promise of ART5803 to directly address neuropsychiatric disease caused by anti-NMDA receptor-targeting pathogenic antibodies,' said Peter Flynn, Ph.D. President and CEO of Arialys Therapeutics. Share 'This study underscores the promise of ART5803 to directly address neuropsychiatric disease caused by anti-NMDA receptor-targeting pathogenic antibodies,' said Peter Flynn, Ph.D. President and CEO of Arialys Therapeutics. 'Despite our understanding of the disease mechanism and its severity, ANRE lacks an approved therapy. Further, there is a growing body of data identifying significant levels of anti-NMDA receptor autoantibodies in subpopulations of patients diagnosed with diseases that result in psychosis and dementia.' 'These data provide compelling evidence that ART5803 can directly block the pathogenic effect of autoantibodies that target the NMDA receptor, resulting in a rapid resolution of symptoms,' said Mitsuyuki (Mickey) Matsumoto, Ph.D., Chief Scientific Officer of Arialys Therapeutics and senior author of the paper. 'Our detailed structural and functional analyses confirm that ART5803 precisely inhibits NMDA receptor internalization induced by the pathogenic autoantibodies, while preserving normal receptor function. In addition, our discovery of a potential molecular mimicry mechanism for anti-NMDA receptor autoantibody generation broadens the understanding of disease initiation and may inform future indication expansion for ART5803.' Anti-NMDA receptor encephalitis (ANRE) is a rare, potentially lethal, poorly managed, and often misdiagnosed neurological disease. ANRE is caused by pathogenic autoantibodies that bind to and crosslink NMDA receptors in the brain, leading to receptor internalization and synaptic dysfunction. The result is a range of debilitating neuropsychiatric symptoms including psychiatric and behavioral alterations, cognitive decline, seizures, coma, and diminished autonomic function. A significant percentage of ANRE patients are pediatric, where NMDA receptor-specific autoantibodies can also result in neurological development deficits. There are no approved therapies for this disease, and current treatments rely on broadly immunosuppressive therapies, which are associated with delayed efficacy and significant side effects. Recent findings have also identified anti-NMDA receptor autoantibodies in other neurological and psychiatric diseases such as schizophrenia, depression, bipolar disorder, and dementia. Arialys is planning clinical assessment of ART5803 in anti-NMDA receptor autoantibody-positive psychosis patients. The company is also currently testing patient samples using a proprietary high-throughput screen for autoantibodies to identify enriched disease indications and subpopulations for future clinical development. ART5803 is a humanized, monovalent IgG1 antibody engineered to selectively bind the GluN1 subunit of the NMDA receptor without disrupting receptor function or causing internalization. In this study, ART5803 demonstrated the ability to potently block NMDA receptor internalization in cellular and neuronal models and reversed both molecular and behavioral hallmarks of disease in a novel marmoset model of ANRE. Notably, ART5803 exhibited rapid onset of action and was well tolerated in vivo. The publication also includes a detailed characterization of ART5803's binding epitope, its mechanism of action, and population pharmacokinetic modeling supporting the feasibility of systemic administration in patients. In addition to demonstrating the therapeutic potential of ART5803, the paper revealed a potential link between infections—specifically Toxoplasma gondii and certain bacterial pathogens—and the generation of pathogenic anti-NMDA receptor autoantibodies. Epitope mapping analysis identified regions of potential molecular mimicry between microbial proteins and the GluN1 subunit of the NMDA receptor, suggesting that infections could serve as environmental triggers for disease initiation. Notably, toxoplasmosis and bacterial infections are well-established risk factors for a range of neuropsychiatric conditions. These findings not only suggest a basis for disease pathogenesis but also support broader therapeutic opportunities for ART5803 across autoimmune neuropsychiatric disorders. ART5803 is currently being evaluated in a Phase 1 clinical trial in healthy volunteers. In February 2025, Arialys announced completion of all single ascending dose (SAD) cohorts and initiation of multiple ascending dose (MAD) cohorts. The company expects to share initial clinical data in the second half of 2025 and initiate Phase 2 proof-of-concept studies. The publication was completed in collaboration with researchers from Astellas Pharma Inc., University of California, Davis, Kitasato University School of Medicine, and Vanadro LLC. About Arialys Therapeutics Arialys was founded by investors Avalon Bioventures, Catalys Pacific and MPM to meaningfully expand the treatment possibilities for neuropsychiatric disorders driven by autoimmune disease. Using a combination of highly sensitive autoantibody detection, patient sampling and receptor structural biology, Arialys has developed a first-in-class precision therapy to specifically block pathogenic autoantibodies in the brain. Arialys is headquartered in La Jolla, California. For more information, visit
Yahoo
a day ago
- Yahoo
Summer Skin Essentials
Time to switch up your skin care regimen for summer MISSION, Kan., June 16, 2025 /PRNewswire/ -- (Family Features) Summer is all about sunshine, vacations and outdoor adventures, but warmer weather and environmental changes can be harsh on your skin. Excessive sun exposure, sweating and dehydration can leave your skin feeling less than its best. Thankfully, with the right skin care essentials, you can maintain glowing, hydrated skin all season long. Explore top solutions for summer skin care, chosen from Herbacin's Skin Solutions and Foot Care lines, and discover how they can restore and protect your skin from summer stressors no matter the adventure at Deep Cleansing for Radiant SkinSummer heat makes oily, sweaty skin more common, leading to clogged pores and dullness. That's why a gentle yet powerful exfoliation is crucial with a solution like Gentle Face Scrub, which is formulated with exfoliating jojoba wax particles to remove dead skin cells and cleanse deep into the pores. Infused with aloe vera, chamomile and marigold, this scrub eliminates impurities while promoting skin regeneration. Plus, it's suitable for all skin types and is free from parabens and mineral oils. How to Use: Apply the scrub 1-2 times per week for instantly smoother, brighter skin. Hydration That Lasts All DayHydration is key to maintaining healthy, youthful skin. Try Daily Skin Moisturizer that offers 24-hour hydration thanks to its hyaluronic acid-rich formula. Enhanced with inositol for elasticity and fucose biopolymer for moisture retention, it deeply nourishes your skin without leaving an oily residue. It's gentle enough for sensitive skin and perfect relief for sun exposure or after a day outdoors. Pro Tip: Apply this lightweight moisturizer as the final step in your morning skin care routine for all-day skin hydration. Soothe and Clear Blemishes QuicklyConsider Anti-Blemish Gel to keep your skin clear and blemish free. Packed with soothing aloe vera, chamomile, marigold, panthenol and bisabolol, this targeted treatment promotes skin healing while drying out blemishes and reducing irritation. Its anti-inflammatory properties make it ideal for tackling acne and preventing future breakouts. How to Use: Apply a small amount to blemishes several times a day until the irritation subsides. Nourishment for Stressed and Rough AreasSun, saltwater and chlorine can cause specific areas of the body, like elbows and hands, to become rough and dehydrated. Designed to restore softness, this Special Care Cream improves skin elasticity in even the driest areas. Enriched with plant-based glycerin, allantoin and vitamin E, this cream provides intensive nourishment and protection without a greasy finish. Essential Tip: Apply regularly to areas prone to dryness for soft, smooth skin all summer. Extra TLC for Your FeetBetween barefoot walks on the beach and sandal season, your feet deserve special attention. Take care of them with Herbacin's Foot Care line, which includes a range of products such as Leg Lotion, Cooling Gel and Foot Cream, designed to revitalize tired legs and feet. Infused with active ingredients like red vine leaves and horse chestnut, these products boost circulation, tone the skin and prevent the formation of calluses and cracks. Step Up Your Routine: Smooth on the Leg Lotion to nourish and protect legs and feet from dehydration. Use the Cooling Gel after a long day to soothe sore legs. Apply Foot Cream overnight to soften and maintain smooth, crack-free skin. Michael Frenchmfrench@ About Family Features Editorial SyndicateA leading source for high-quality food, lifestyle and home and garden content, Family Features provides readers with topically and seasonally relevant tips, takeaways, information, recipes, videos, infographics and more. Find additional articles and information at and View original content to download multimedia: SOURCE Family Features Editorial Syndicate
Hamilton Spectator
a day ago
- Hamilton Spectator
UN rights chief urges governments to ‘wake up' to ‘horrifying' suffering in Gaza
GENEVA (AP) — The U.N. human rights chief said Israel's warfare in Gaza is inflicting 'horrifying, unconscionable suffering' on Palestinians and urged government leaders on Monday to 'wake up' and exert pressure to bring an end to the conflict. 'The facts speak for themselves,' said Volker Türk. 'Everyone in government needs to wake up to what is happening in Gaza. All those with influence must exert maximum pressure on Israel and Hamas, to put an end to this unbearable suffering.' Türk made the comments at the opening of the latest Human Rights Council session in a broad address that also raised concerns about escalating conflict between Iran and Israel , the fallout from U.S. tariffs , and China's human rights record — alongside wars and conflict in places like Sudan and Ukraine . As the United Nations High Commissioner for Human Rights — who has regularly spoken out about bloodshed in Gaza and called for the release of Israeli hostages held by armed Palestinian militants — Türk used some of his most forceful words yet to highlight the Mideast violence . 'Israel's means and methods of warfare are inflicting horrifying, unconscionable suffering on Palestinians in Gaza,' he told the 47-member-country body, which Israeli authorities have regularly accused of anti-Israel bias. The Trump administration has kept the United States, Israel's top ally, out of the council proceedings. Israel's military campaign since the deadly Oct. 7, 2023, Hamas-led attacks in Israel has killed over 55,300 Palestinians, according to Gaza's Health Ministry. It says that women and children make up most of the dead, but it does not distinguish between civilians and combatants. The Israeli diplomatic mission in Geneva responded by accusing Türk and his office of been 'relentless in making irresponsible and uneducated statements regarding Israel's conduct of hostilities — including reliance on information propagated by terrorist organizations.' It called on Türk to 'condemn Hamas's declared strategy to maximize harm to the population in Gaza.' In Brussels, medical aid charity Doctors Without Borders appealed to European Union leaders to use what leverage they have over Israel to end the siege of Gaza. Secretary-General Christopher Lockyear described Gaza as a 'hell on earth,' and said that almost two years of relentless bombardment has turned 'this narrow strip of land into a graveyard of shattered hospitals, mass graves and destroyed neighborhoods.' Aid deliveries organised by the U.N. were cut off in mid-March, and violence has accompanied distributions of food from the recently created Gaza Humanitarian Foundation , which has U.S. and Israeli backing. Beyond the suffering of inflicted on in Gaza, Doctors Without Borders said its international staffers are living often on one meal a day, and some have been admitted to their own facilities for treatment. The EU is the world's biggest donor of aid to the Palestinians but has little real leverage over Israel. The bloc's 27 member states are divided in their approach to the conflict, although concern over the plight of Gazans has grown as the siege has dragged on. In his speech, Türk also bemoaned an increase in civilian casualties in Ukraine, nearly 3 1/2 years after Russia's full-scale invasion. He denounced executions without a fair trial and 'wide-scale sexual violence, including against children' in Sudan. Without mentioning U.S. President Donald Trump by name, Türk likened the tariffs imposed by the Trump administration in April to 'a high-stakes poker game, with the global economy as the bank.' 'But the shockwaves of a trade war will hit least developed countries with the force of a tsunami,' he said, warning of a potentially 'devastating' impact on exporters in Asia, and the prospect of higher costs for food, healthcare and education in places. Türk expressed concerns about U.S. deportations of non-nationals, including to third countries, and called on authorities to respect the right to peaceful assembly . The council session, which has been shortened by 2 1/2 days because of funding issues at the U.N., is set to run through July 9. The Geneva-based council is the U.N.'s top human rights body. ___ Associated Press writer Lorne Cook in Brussels contributed to this report. Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .
